1. Biomarkers of the Insulin-Like Growth Factor Pathway Predict Progression and Outcome in Lung Cancer 
David D. Shersher, MD, Michael S. Vercillo, MD, Cristina Fhied, MS, Sanjib Basu, PhD, Omid Rouhi, MD, Brett Mahon, MD, John S. Coon, MD, PhD, William H. Warren, MD, L. Penfield Faber, MD, Edward Hong, MD, Philip Bonomi, MD, Michael J. Liptay, MD, Jeffrey A. Borgia, PhD 
The Annals of Thoracic Surgery 
Volume 92, Issue 5, Pages (November 2011)
DOI: /j.athoracsur
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Concentrations of (A) insulin-like growth factor binding protein 5(IGFBP5) and (B) IGFBP7 are shown with respect to lymph node status (0 = N0 disease; 1 = N1 to N3 disease. (C) IGFBP5 concentration is shown with respect to disease recurrence (0 = no incidence of disease recurrence for 2 years; 1 = recurrent disease ≤ 2 year). The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles, respectively, and the whiskers mark the 90th and 10th percentiles.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Kaplan-Meier curve is shown for insulin-like growth factor binding protein (IGFBP5) concentrations with respect to recurrence-free survival in all patients. Group 1(solid line) = IGFBP5 concentration ≤ 318 ng/mL (n = 57); group 2(dotted line) = IGFBP5 concentration > 318 ng/mL (n = 28).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions